Lake Street analyst Thomas Flaten raised the firm’s price target on Evaxion Biotech (EVAX) to $11 from $6 and keeps a Buy rating on the shares after the company announced two-year Phase 2 data for its personalized cancer vaccine, EVX-01, in advanced melanoma. The two-year EVX-01 data and Merck’s (MRK) option exercise for EVX-B3 further validate Evaxion’s platform, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Buy Recommendation for Evaxion Biotech Amid Promising Phase 2 Study Results and Future Potential
- Evaxion Biotech trading resumes
- Evaxion Biotech trading halted, volatility trading pause
- Evaxion Biotech Expands Capital Through ADS Sales and Warrant Exercises
- Evaxion Reports 75% Response Rate in Cancer Vaccine Trial